The August 21, 2026 deadline creates a binary catalyst: a rescue deal (sale, licensing, or equity infusion) could stabilize the stock, while failure to secure an acceptable transaction likely triggers a default and potential bankruptcy. Traders should monitor for press releases or 8-Ks regarding a definitive agreement before the deadline.
Price Chart
Executive Summary
BioXcel Therapeutics entered its Twelfth Amendment to the Oaktree credit agreement, extending the deadline to August 21, 2026, to secure a transaction that repays all obligations or is an acceptable alternative capital solution. The minimum liquidity covenant was simultaneously slashed from $6.25M to $3.0M, signaling severe cash burn and a highly constrained negotiating position with lenders. The company is effectively on a short leash to find a rescue deal or face default.
Key Financial Metrics
Key Facts
- The Twelfth Amendment requires BioXcel to enter definitive agreements for a full repayment or alternative capital solution by August 21, 2026, extended from August 10, 2026.
- Lenders reduced the minimum liquidity covenant from $6.25 million to $3.0 million, reflecting the company's deteriorating cash position.
- The amendment references a history of prior amendments (Fifth through Eleventh) and declining liquidity thresholds, indicating a pattern of financial distress.
- The filing includes commercial tort claims pledged as collateral, including litigation against Cognitive Research, Caitlin Meyer, and Segal Institute for Clinical Research.
Financial Impact
Minimum liquidity covenant reduced from $6.25M to $3.0M; company must secure a full-repayment or alternative-capital transaction by August 21, 2026, or face potential default under the Oaktree credit agreement.
Risk Factors
- Failure to secure an acceptable transaction by August 21, 2026, could lead to default and acceleration of all obligations under the Oaktree credit agreement.
- The reduced $3.0M minimum liquidity covenant leaves virtually no cash cushion, increasing the risk of a distressed sale or equity dilution on punitive terms.
- The company has a history of serial amendments, suggesting lenders may be unwilling to provide further forbearance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-093710 |
| Document: tm2622818d1_ex10-1.htm | 0001104659-26-093710 |
| Document: 0001104659-26-093710-index-headers.html | 0001104659-26-093710 |
| Document: 0001104659-26-093710-index.html | 0001104659-26-093710 |
| Document: 0001104659-26-093710.txt | 0001104659-26-093710 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 1, 2026 7w ago | 8-K | $0.1370 | awaiting T+60 | — | — |
Aug 28, 2026 8w ago | Press Release | $0.1814 | awaiting T+60 | — | — |
Aug 25, 2026 8w ago | 8-K | $0.7422 | awaiting T+60 | — | — |
Aug 11, 2026 10w ago | 8-K | $0.9320 | awaiting T+60 | — | — |
Aug 3, 2026 12w ago | 8-K | $0.8480 | awaiting T+60 | — | — |
Jul 6, 2026 16w ago | 8-K | $1.10 | awaiting T+60 | — | — |
May 22, 2026 22w ago | Insider Cluster | $1.22 $0.8274 | ▲ +32.18% | ▲ +34.91% | — |
May 20, 2026 22w ago | 144 | $1.14 $0.8900 | ▼ −21.93% | ▼ −26.23% | — |
May 15, 2026 23w ago | 8-K | $1.14 $0.9319 | ▼ −18.25% | ▼ −22.77% | — |
May 15, 2026 23w ago | Press Release | $1.14 $0.9319 | ▲ +18.25% | ▲ +22.77% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers